David K Chang

List of Publications by Year
in descending order

82 papers	15,193 citations	66234 42 h-index	60497 81 g-index
86 all docs	86 docs citations	86 times ranked	20786 citing authors

#	Article	IF	Citations
1	ICGC-ARGO precision medicine: familial matters in pancreatic cancer. Lancet Oncology, The, 2022, 23, 25-26.	5.1	6
2	Spatial expression of IKK-alpha is associated with a differential mutational landscape and survival in primary colorectal cancer. British Journal of Cancer, 2022, , .	2.9	2
3	ICGC-ARGO precision medicine: targeted therapy according to longitudinal assessment of tumour heterogeneity in colorectal cancer. Lancet Oncology, The, 2022, 23, 463-464.	5.1	3
4	Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer. Gastroenterology, 2021, 160, 362-377.e13.	0.6	90
5	Molecular Subtyping of Pancreatic Cancer. , 2021, , 305-319.		0
6	DNA methylation patterns identify subgroups of pancreatic neuroendocrine tumors with clinical association. Communications Biology, 2021, 4, 155.	2.0	26
7	Muscle-Derived Cytokines Reduce Growth, Viability and Migratory Activity of Pancreatic Cancer Cells. Cancers, 2021, 13, 3820.	1.7	12
8	Homologous Recombination Deficiency in Pancreatic Cancer: A Systematic Review and Prevalence Meta-Analysis. Journal of Clinical Oncology, 2021, 39, 2617-2631.	0.8	63
9	Role of PLEXIND1/TGFÎ² Signaling Axis in Pancreatic Ductal Adenocarcinoma Progression Correlates with the Mutational Status of KRAS. Cancers, 2021, 13, 4048.	1.7	4
10	Molecular Subtyping and Precision Medicine for Pancreatic Cancer. Journal of Clinical Medicine, 2021, 10, 149.	1.0	34
11	Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage. Nature Communications, 2021, 12, 6738.	5.8	10
12	Precision Oncology in Surgery. Annals of Surgery, 2020, 272, 366-376.	2.1	48
13	Clinical and Molecular Risk Factors for Recurrence Following Radical Surgery of Well-Differentiated Pancreatic Neuroendocrine Tumors. Frontiers in Medicine, 2020, 7, 385.	1.2	7
14	Defining the clinical genomic landscape for real-world precision oncology. Genomics, 2020, 112, 5324-5330.	1.3	16
15	HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer. Cell Reports, 2020, 31, 107625.	2.9	78
16	Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer. Cancer Cell, 2020, 38, 198-211.e8.	7.7	99
17	An unbiased highâ€throughput drug screen reveals a potential therapeutic vulnerability in the most lethal molecular subtype of pancreatic cancer. Molecular Oncology, 2020, 14, 1800-1816.	2.1	10
18	Reasons to be testing: the dawn of complex molecular profiling in routine oncology practice. Annals of Oncology, 2019, 30, 1691-1694.	0.6	12

#	Article	IF	Citations
19	Molecular subtypes of pancreatic cancer. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 207-220.	8.2	573
20	Feasibility and clinical utility of endoscopic ultrasound guided biopsy of pancreatic cancer for next-generation molecular profiling. Chinese Clinical Oncology, 2019, 8, 16-16.	0.4	33
21	Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer. Gut, 2018, 67, 2142-2155.	6.1	100
22	Interrogating open issues in cancer precision medicine with patient-derived xenografts. Nature Reviews Cancer, 2017, 17, 254-268.	12.8	527
23	Whole-genome landscape of pancreatic neuroendocrine tumours. Nature, 2017, 543, 65-71.	13.7	716
24	Recurrent noncoding regulatory mutations in pancreatic ductal adenocarcinoma. Nature Genetics, 2017, 49, 825-833.	9.4	55
25	Pancreatic Cancer Genomes: Implications for Clinical Management and Therapeutic Development. Clinical Cancer Research, 2017, 23, 1638-1646.	3.2	136
26	BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer. British Journal of Cancer, 2017, 116, 1021-1026.	2.9	61
27	Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. Cancer Cell, 2017, 32, 185-203.e13.	7.7	1,428
28	Lost in translation: returning germline genetic results in genome-scale cancer research. Genome Medicine, 2017, 9, 41.	3.6	27
29	Hypermutation In Pancreatic Cancer. Gastroenterology, 2017, 152, 68-74.e2.	0.6	174
30	The role of induction chemotherapy + chemoradiotherapy in localised pancreatic cancer: initial experience in Scotland. Journal of Gastrointestinal Oncology, 2017, 8, 683-695.	0.6	12
31	PDX1 dynamically regulates pancreatic ductal adenocarcinoma initiation and maintenance. Genes and Development, 2016, 30, 2669-2683.	2.7	88
32	Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma. Scientific Reports, 2016, 6, 35848.	1.6	127
33	Gastric cancer: <scp>A</scp>ustralian outcomes of multiâ€modality treatment with curative intent. ANZ Journal of Surgery, 2016, 86, 386-390.	0.3	3
34	Resolution of Novel Pancreatic Ductal Adenocarcinoma Subtypes by Global Phosphotyrosine Profiling. Molecular and Cellular Proteomics, 2016, 15, 2671-2685.	2.5	29
35	CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma. Cancer Cell, 2016, 29, 832-845.	7.7	645
36	Ampullary Cancers Harbor ELF3 Tumor Suppressor Gene Mutations and Exhibit Frequent WNT Dysregulation. Cell Reports, 2016, 14, 907-919.	2.9	107

#	Article	IF	Citations
37	Genomic analyses identify molecular subtypes of pancreatic cancer. Nature, 2016, 531, 47-52.	13.7	2,700
38	Targeting the <scp>LOX</scp> / <scp>hypoxia</scp> axis reverses many of the features that make pancreatic cancer deadly: inhibition of <scp>LOX</scp> abrogates metastasis and enhances drug efficacy. EMBO Molecular Medicine, 2015, 7, 1063-1076.	3.3	223
39	The epigenetic agents suberoylanilide hydroxamic acid and 5-AZA-2â€² deoxycytidine decrease cell proliferation, induce cell death and delay the growth of MiaPaCa2 pancreatic cancer cells in vivo. International Journal of Oncology, 2015, 46, 2223-2230.	1.4	17
40	Pancreatic cancer genomics: where can the science take us?. Clinical Genetics, 2015, 88, 213-219.	1.0	13
41	Inherited Susceptibility to Pancreatic Cancer in the Era of Next-Generation Sequencing. Gastroenterology, 2015, 148, 496-498.	0.6	3
42	Whole genomes redefine the mutational landscape of pancreatic cancer. Nature, 2015, 518, 495-501.	13.7	2,132
43	Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial. Clinical Cancer Research, 2015, 21, 2029-2037.	3.2	209
44	Cancer Genetics and Implications for Clinical Management. Surgical Clinics of North America, 2015, 95, 919-934.	0.5	6
45	Asian gastric cancer patients show superior survival: the experiences of a single Australian center. Gastric Cancer, 2015, 18, 256-261.	2.7	15
46	Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer. Oncotarget, 2015, 6, 44551-44562.	0.8	37
47	Adjuvant chemotherapy in elderly patients with pancreatic cancer. British Journal of Cancer, 2014, 110, 313-319.	2.9	64
48	Stratified Medicine for Pancreatic Cancer. , 2014, , 807-814.		0
49	Clinical and pathologic features of familial pancreatic cancer. Cancer, 2014, 120, 3669-3675.	2.0	53
50	Can we move towards personalised pancreatic cancer therapy?. Expert Review of Gastroenterology and Hepatology, 2014, 8, 335-338.	1.4	5
51	Genomeâ€wide DNA methylation patterns in pancreatic ductal adenocarcinoma reveal epigenetic deregulation of SLITâ€ROBO, ITGA2 and MET signaling. International Journal of Cancer, 2014, 135, 1110-1118.	2.3	192
52	Targeting mTOR dependency in pancreatic cancer. Gut, 2014, 63, 1481-1489.	6.1	107
53	Mining the genomes of exceptional responders. Nature Reviews Cancer, 2014, 14, 291-292.	12.8	38
54	Returning individual research results for genome sequences of pancreatic cancer. Genome Medicine, 2014, 6, 42.	3.6	25

#	Article	IF	Citations
55	Pancreatic cancer genomics. Current Opinion in Genetics and Development, 2014, 24, 74-81.	1.5	50
56	Personalising pancreas cancer treatment: When tissue is the issue. World Journal of Gastroenterology, 2014, 20, 7849.	1.4	22
57	Understanding pancreatic cancer genomes. Journal of Hepato-Biliary-Pancreatic Sciences, 2013, 20, 549-556.	1.4	31
58	Clinical and molecular characterization of HER2 amplified-pancreatic cancer. Genome Medicine, 2013, 5, 78.	3.6	97
59	Histomolecular Phenotypes and Outcome in Adenocarcinoma of the Ampulla of Vater. Journal of Clinical Oncology, 2013, 31, 1348-1356.	0.8	142
60	The histone deacetylase SIRT2 stabilizes Myc oncoproteins. Cell Death and Differentiation, 2013, 20, 503-514.	5.0	171
61	Neuropilin-2 Promotes Extravasation and Metastasis by Interacting with Endothelial Î±5 Integrin. Cancer Research, 2013, 73, 4579-4590.	0.4	97
62	Reply to G.F. Arroyo. Journal of Clinical Oncology, 2013, 31, 3843-3844.	0.8	0
63	Somatic Point Mutation Calling in Low Cellularity Tumors. PLoS ONE, 2013, 8, e74380.	1.1	67
64	The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature, 2012, 486, 266-270.	13.7	297
65	The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Annals of Oncology, 2012, 23, 1713-1722.	0.6	240
66	<i>Sleeping Beauty</i> mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 5934-5941.	3.3	201
67	RON is not a prognostic marker for resectable pancreatic cancer. BMC Cancer, 2012, 12, 395.	1.1	17
68	Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature, 2012, 491, 399-405.	13.7	1,741
69	Recruitment and Activation of Pancreatic Stellate Cells from the Bone Marrow in Pancreatic Cancer: A Model of Tumor-Host Interaction. PLoS ONE, 2011, 6, e26088.	1.1	55
70	Retinoid Signaling in Pancreatic Cancer, Injury and Regeneration. PLoS ONE, 2011, 6, e29075.	1.1	20
71	Clinical and immunohistochemical features of 34 solid pseudopapillary tumors of the pancreas. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 267-274.	1.4	53
72	Preclinical strategies to define predictive biomarkers for therapeutically relevant cancer subtypes. Human Genetics, 2011, 130, 93-101.	1.8	13

#	Article	IF	Citations
73	Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects. Oncogene, 2010, 29, 5957-5968.	2.6	76
74	Synoptic reporting improves histopathological assessment of pancreatic resection specimens. Pathology, 2009, 41, 161-167.	0.3	94
75	Margin Clearance and Outcome in Resected Pancreatic Cancer. Journal of Clinical Oncology, 2009, 27, 2855-2862.	0.8	296
76	Taking optical biopsies with confocal endomicroscopy. Journal of Gastroenterology and Hepatology (Australia), 2009, 24, 1701-1703.	1.4	6
77	Role of endoscopic ultrasound in pancreatic cancer. Expert Review of Gastroenterology and Hepatology, 2009, 3, 293-303.	1.4	12
78	Expression of S100A2 Calcium-Binding Protein Predicts Response to Pancreatectomy for Pancreatic Cancer. Gastroenterology, 2009, 137, 558-568.e11.	0.6	82
79	Real Time Intraoperative Confocal Laser Microscopy-Guided Surgery. Annals of Surgery, 2009, 249, 735-737.	2.1	22
80	Improving outcomes for operable pancreatic cancer: Is access to safer surgery the problem?. Journal of Gastroenterology and Hepatology (Australia), 2008, 23, 1036-1045.	1.4	29
81	Individualizing therapy for pancreatic cancer. Journal of Gastroenterology and Hepatology (Australia), 2008, 23, 1779-1782.	1.4	6
82	Aniseikonia, metamorphopsia and perceived entoptic pattern: some effects of a macular epiretinal membrane, and the subsequent spontaneous separation of the membrane. Ophthalmic and Physiological Optics, 1995, 15, 339-343.	1.0	23